🎉 M&A multiples are live!
Check it out!

Scinopharm Taiwan Valuation Multiples

Discover revenue and EBITDA valuation multiples for Scinopharm Taiwan and similar public comparables like Galapagos, Pharming, and Vivoryon Therapeutics.

Scinopharm Taiwan Overview

About Scinopharm Taiwan

Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.


Founded

1997

HQ

Taiwan
Employees

748

Website

scinopharm.com

Financials

LTM Revenue $104M

LTM EBITDA n/a

EV

$326M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Scinopharm Taiwan Financials

Scinopharm Taiwan has a last 12-month revenue of $104M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Scinopharm Taiwan achieved revenue of $103M and an EBITDA of $27.5M.

Scinopharm Taiwan expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Scinopharm Taiwan valuation multiples based on analyst estimates

Scinopharm Taiwan P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $96.2M $103M XXX XXX XXX
Gross Profit $37.8M $36.7M XXX XXX XXX
Gross Margin 39% 36% XXX XXX XXX
EBITDA $24.7M $27.5M XXX XXX XXX
EBITDA Margin 26% 27% XXX XXX XXX
Net Profit $10.7M $8.7M XXX XXX XXX
Net Margin 11% 8% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Scinopharm Taiwan Stock Performance

As of April 15, 2025, Scinopharm Taiwan's stock price is TWD 18 (or $1).

Scinopharm Taiwan has current market cap of TWD 14.3B (or $431M), and EV of TWD 10.8B (or $326M).

See Scinopharm Taiwan trading valuation data

Scinopharm Taiwan Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$326M $431M XXX XXX XXX XXX $0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Scinopharm Taiwan Valuation Multiples

As of April 15, 2025, Scinopharm Taiwan has market cap of $431M and EV of $326M.

Scinopharm Taiwan's trades at 3.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Scinopharm Taiwan's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Scinopharm Taiwan and 10K+ public comps

Scinopharm Taiwan Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $326M XXX XXX XXX
EV/Revenue 3.2x XXX XXX XXX
EV/EBITDA 11.9x XXX XXX XXX
P/E 42.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 23.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Scinopharm Taiwan Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Scinopharm Taiwan Valuation Multiples

Scinopharm Taiwan's NTM/LTM revenue growth is 3%

Scinopharm Taiwan's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $39K for the same period.

Over next 12 months, Scinopharm Taiwan's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Scinopharm Taiwan's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Scinopharm Taiwan and other 10K+ public comps

Scinopharm Taiwan Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 7% XXX XXX XXX XXX
EBITDA Margin 27% XXX XXX XXX XXX
EBITDA Growth 11% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 30% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $39K XXX XXX XXX XXX
S&M Expenses to Revenue 4% XXX XXX XXX XXX
G&A Expenses to Revenue 11% XXX XXX XXX XXX
R&D Expenses to Revenue 13% XXX XXX XXX XXX
Opex to Revenue 29% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Scinopharm Taiwan Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Contract Research & Manufacturing comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Scinopharm Taiwan M&A and Investment Activity

Scinopharm Taiwan acquired  XXX companies to date.

Last acquisition by Scinopharm Taiwan was  XXXXXXXX, XXXXX XXXXX XXXXXX . Scinopharm Taiwan acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Scinopharm Taiwan

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Scinopharm Taiwan

When was Scinopharm Taiwan founded? Scinopharm Taiwan was founded in 1997.
Where is Scinopharm Taiwan headquartered? Scinopharm Taiwan is headquartered in Taiwan.
How many employees does Scinopharm Taiwan have? As of today, Scinopharm Taiwan has 748 employees.
Is Scinopharm Taiwan publicy listed? Yes, Scinopharm Taiwan is a public company listed on TAI.
What is the stock symbol of Scinopharm Taiwan? Scinopharm Taiwan trades under 1789 ticker.
When did Scinopharm Taiwan go public? Scinopharm Taiwan went public in 2011.
Who are competitors of Scinopharm Taiwan? Similar companies to Scinopharm Taiwan include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Scinopharm Taiwan? Scinopharm Taiwan's current market cap is $431M
What is the current revenue of Scinopharm Taiwan? Scinopharm Taiwan's last 12-month revenue is $104M.
What is the current EV/Revenue multiple of Scinopharm Taiwan? Current revenue multiple of Scinopharm Taiwan is 3.1x.
What is the current revenue growth of Scinopharm Taiwan? Scinopharm Taiwan revenue growth between 2023 and 2024 was 7%.
Is Scinopharm Taiwan profitable? Yes, Scinopharm Taiwan is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.